EXV4:XETRA:XETRA-iShares STOXX Europe 600 Health Care UCITS ETF (DE) (EUR)

ETF | Others |

Last Closing

USD 120.08

Change

-0.96 (-0.79)%

Market Cap

USD 0.70B

Volume

0.01M

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

NA

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-09-30 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
XM1D:XETRA Xtrackers MSCI Japan UCITS ETF..

-0.06 (-0.11%)

USD 501.76B
XM1D:XETRA Xtrackers MSCI Japan UCITS ETF..

-0.06 (-0.11%)

USD 501.76B
LCUJ:XETRA Lyxor Core MSCI Japan (DR) UCI..

-0.02 (-0.15%)

USD 191.96B
LCUJ:XETRA Lyxor Core MSCI Japan (DR) UCI..

-0.02 (-0.15%)

USD 191.96B
PRAJ:XETRA Amundi Index Solutions - Amund..

-0.03 (-0.11%)

USD 177.46B
PR1J:XETRA Amundi Prime Japan UCITS ETF D..

-0.03 (-0.11%)

USD 177.46B
PRAJ:XETRA Amundi Index Solutions - Amund..

-0.03 (-0.11%)

USD 177.46B
PR1J:XETRA Amundi Prime Japan UCITS ETF D..

-0.03 (-0.11%)

USD 177.46B
XDJP:XETRA Xtrackers Nikkei 225 UCITS ETF..

-0.10 (-0.39%)

USD 157.79B
XDJP:XETRA Xtrackers Nikkei 225 UCITS ETF..

-0.10 (-0.39%)

USD 157.79B

ETFs Containing EXV4:XETRA

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 13.73% 69% C- 69% C-
Dividend Return 1.17% 40% F 26% F
Total Return 14.90% 72% C 72% C
Trailing 12 Months  
Capital Gain 14.17% 46% F 50% F
Dividend Return 1.41% 37% F 25% F
Total Return 15.58% 49% F 51% F
Trailing 5 Years  
Capital Gain 48.50% 64% D 65% D
Dividend Return 5.76% 63% D 34% F
Total Return 54.26% 67% D+ 66% D+
Average Annual (5 Year Horizon)  
Capital Gain 6.42% N/A N/A 55% F
Dividend Return 7.35% N/A N/A 57% F
Total Return 0.94% N/A N/A 43% F
Risk Return Profile  
Volatility (Standard Deviation) 8.43% N/A N/A 73% C
Risk Adjusted Return 87.19% N/A N/A 89% A-
Market Capitalization 0.70B 71% C- 63% D

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:

There is nothing we particularly dislike